Maves review

The entry figure here is genuinely low, and the shape of the catalog explains some of why. Maves is built around performance and optimization rather than weight loss as a standalone concern — muscle, energy, sleep and longevity get equal billing with fat loss, and the GLP-1 line sits inside that range rather than being the whole business. If you want one prescriber handling several things at once that is a real convenience, and the quality claims are more specific than most: independent potency testing is asserted, not just licensing, and the state coverage is stated with its exclusions rather than rounded up. The pricing is where you have to be careful. One figure covers a product called simply GLP-1 treatments, and the site names both molecules elsewhere without attaching a price to either. Everywhere else that sells both publishes two numbers, because the dual agonist costs more to compound, which means one low floor cannot be true of both at the same price. Either it is the single-agonist number with the other dearer by an amount the page does not state, or it buys a configuration the page does not describe. No milligram sits behind it either, so if you are holding a deliberately small dose you have a low number you cannot attach to a quantity — a better problem than a high one, and still a problem.

Vs median

$86/mo below the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not confirmed

Labs

Not required

Pricing

Check plan terms

Maves does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

The entry figure here is genuinely low, and the shape of the catalog explains some of why. Maves is built around performance and optimization rather than weight loss as a standalone concern — muscle, energy, sleep and longevity get equal billing with fat loss, and the GLP-1 line sits inside that range rather than being the whole business. For a reader who wants one prescriber handling several things at once that is a real convenience, and the quality claims are more specific than most: independent potency testing is asserted, not just licensing, and the state coverage is stated with its exclusions rather than rounded up to fifty. The pricing is where a reader has to be careful. One figure covers a product called simply GLP-1 treatments, and the site names both molecules elsewhere without attaching a price to either. Everywhere else that sells both publishes two numbers, because the dual agonist costs more to compound, which means an $89 floor cannot be true of both at the same price. Either it is the semaglutide number with the other dearer by an amount the page does not state, or it buys a configuration the page does not describe. No milligram sits behind it either, so a reader holding a deliberately small dose has a low number they cannot attach to a quantity, which is a better problem than a high one and still a problem.

One floor covers both molecules, so the cheaper of the two cannot be identified.

• The figure is a starting point with no ceiling published.
• No dose sits behind it, so it cannot be matched to an amount of drug.

Maves is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• Microdosing semaglutide
• Microdosing tirzepatide
• The true annual cost of a plan
• What a flat price costs at a low dose